uric acid has been researched along with Hepatitis C, Chronic in 8 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Hepatitis C, Chronic: INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection." | 7.85 | Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. ( Kim, HJ; Lee, HW; Oh, IS; Won, JW, 2017) |
| "Hyperuricemia has been reported as being an adverse effect of pegylated-interferon-alpha2b (Peg-IFNalpha2b) and ribavirin combination therapy for chronic hepatitis C and hyperuricemic changes occur in some patients during the therapy." | 7.74 | Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C. ( Enjoji, M; Higuchi, N; Horikawa, Y; Kato, M; Kinukawa, N; Kotoh, K; Nakamuta, M; Tajiri, H; Takayanagi, R; Ueda, A; Yamashita, N, 2008) |
| " The changes in serum uric acid (SUA) levels in chronic hepatitis C patients who receive antivirals are not well understood." | 3.96 | Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. ( Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Jang, TY; Liang, PC; Lin, YH; Lin, ZY; Tsai, PC; Yeh, ML; Yu, ML, 2020) |
| " The association between chronic hepatitis C (CHC) and uric acid levels has rarely been investigated." | 3.88 | Association of hyperuricemia with disease severity in chronic hepatitis C patients. ( Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Jang, TY; Lin, ZY; Yeh, ML; Yu, ML, 2018) |
| "Combined treatment of pegylated interferon-α (PEG-IFN) and ribavirin (RBV) has long been accepted as the standard treatment for chronic hepatitis C virus (HCV) infection." | 3.85 | Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection. ( Kim, HJ; Lee, HW; Oh, IS; Won, JW, 2017) |
| "Several works observed a link between uric acid serum levels and clinical and histological features of nonalcoholic fatty liver disease." | 3.78 | Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. ( Cabibi, D; Cammà, C; Craxì, A; Macaluso, FS; Marco, VD; Petta, S, 2012) |
| "Hyperuricemia has been reported as being an adverse effect of pegylated-interferon-alpha2b (Peg-IFNalpha2b) and ribavirin combination therapy for chronic hepatitis C and hyperuricemic changes occur in some patients during the therapy." | 3.74 | Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C. ( Enjoji, M; Higuchi, N; Horikawa, Y; Kato, M; Kinukawa, N; Kotoh, K; Nakamuta, M; Tajiri, H; Takayanagi, R; Ueda, A; Yamashita, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, TY | 2 |
| Huang, CI | 2 |
| Yeh, ML | 2 |
| Liang, PC | 1 |
| Tsai, PC | 1 |
| Lin, YH | 1 |
| Hsieh, MY | 1 |
| Hou, NJ | 1 |
| Lin, ZY | 2 |
| Chen, SC | 2 |
| Huang, JF | 2 |
| Dai, CY | 2 |
| Huang, CF | 2 |
| Chuang, WL | 2 |
| Yu, ML | 2 |
| Oh, IS | 1 |
| Won, JW | 1 |
| Kim, HJ | 1 |
| Lee, HW | 1 |
| Hsieh, MH | 1 |
| Petta, S | 1 |
| Macaluso, FS | 1 |
| Cammà, C | 1 |
| Marco, VD | 1 |
| Cabibi, D | 1 |
| Craxì, A | 1 |
| Yamashita, N | 1 |
| Enjoji, M | 1 |
| Kotoh, K | 1 |
| Kato, M | 1 |
| Ueda, A | 1 |
| Horikawa, Y | 1 |
| Tajiri, H | 1 |
| Higuchi, N | 1 |
| Kinukawa, N | 1 |
| Nakamuta, M | 1 |
| Takayanagi, R | 1 |
| Pellicano, R | 1 |
| Puglisi, G | 1 |
| Ciancio, A | 1 |
| Balzola, F | 1 |
| Saracco, G | 1 |
| Ciccone, G | 1 |
| Baldi, I | 1 |
| Abate, ML | 1 |
| Smedile, A | 1 |
| Rizzetto, M | 1 |
| Fontana, RJ | 1 |
| El-Zayadi, AR | 1 |
| Selim, O | 1 |
| Hamdy, H | 1 |
| El-Tawil, A | 1 |
| Moustafa, H | 1 |
8 other studies available for uric acid and Hepatitis C, Chronic
| Article | Year |
|---|---|
Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents.
Topics: Aged; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Hyperuricemia; Liver Cirrhosis; Male; | 2020 |
Clinical implication of serum uric acid level in pegylated interferon and ribavirin combination therapy for chronic hepatitis C infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon | 2017 |
Association of hyperuricemia with disease severity in chronic hepatitis C patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Female; Hepatitis | 2018 |
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.
Topics: Biomarkers; Biopsy; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperuricemia; M | 2012 |
Investigation of hyperuricemia during pegylated-interferon-alpha2b plus ribavirin combination therapy in patients with chronic hepatitis C.
Topics: Aged; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hyperuricemia; Interferon alp | 2008 |
Is serum uric acid a predictive factor of response to IFN-treatment in patients with chronic hepatitis C infection?
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver | 2008 |
Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C.
Topics: Adult; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney | 2001 |
Heavy cigarette smoking induces hypoxic polycythemia (erythrocytosis) and hyperuricemia in chronic hepatitis C patients with reversal of clinical symptoms and laboratory parameters with therapeutic phlebotomy.
Topics: Adult; Hepatitis C, Chronic; Humans; Male; Polycythemia; Smoking; Uric Acid | 2002 |